Search

Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.

Read more

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

Read more

Call for interest — EHA Exam Question Writers Group

The call for interest closed on October 7, 2024. EHA would like to appoint four new members of the European Hematology Exam Question Writers Group.

Read more

EHA Innovation Grant draft

The call will open on October 15, 2024, at 12:00 (CEST).

Read more

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

Read more

EU funding calls for hematology

Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…

Read more